Skip to main content Skip to footer
LikardaLikarda
  • About
    • Our Story
    • Our Strategy
    • Our Leadership
    • Careers
  • Solutions
    • Core-Shell Spherification® (CSS®)
      • CSS® Feasibility Study
      • CSS® Encapsulation for Preclinical and Animal Studies
    • Cell Therapies
      • VitaCell™
      • ViscoCell™
      • EnduraCell™
    • Cryopreservation & Logistics
      • LiberaCell™
      • AegisCell™
      • AegisBio™
    • Large & Small Molecules
      • NovoSphere™
      • Provia™
  • Encapsulation Technologies
    • Predictive Polymer Analytics™ (PPA™)
    • CSS® Encapsulation Equipment
    • Hydrogel & Cell Therapy Consultation
  • Therapeutic Challenges
    • Lack of Persistence
    • Poor Yield & Function after Freezing Cells
    • Immune Rejection of Encapsulant
    • Lack of Biocompatibility
    • Regulatory Hurdles
    • Different Therapies Need Unique Microenvironments
  • Success Stories
    • Antibodies (NovoSphere™)
    • Osteoarthritis Therapy (ViscoCell™)
    • Diabetes Treatment (EnduraCell™)
    • Cryopreservation (LiberaCell™)
    • Liver Disease (EnduraCell™)
    • CAR-T Cells (VitaCell™)
    • Cryopreservation (AegisCell™)
    • Extending the Life of Fresh Cells (LiberaCell™)
    • View All
  • Resources
    • Research & White Papers
    • News & Upcoming Events
    • Bio-Blog / Tech Notes
    • Videos & Webinars
  • Partner With Us
    • Contact Us
    • Investors
Follow Us:
Likarda
  • About
    • Our Story
    • Our Strategy
    • Our Leadership
    • Careers
  • Solutions
    • Core-Shell Spherification® (CSS®)
      • CSS® Feasibility Study
      • CSS® Encapsulation for Preclinical and Animal Studies
    • Cell Therapies
      • VitaCell™
      • ViscoCell™
      • EnduraCell™
    • Cryopreservation & Logistics
      • LiberaCell™
      • AegisCell™
      • AegisBio™
    • Large & Small Molecules
      • NovoSphere™
      • Provia™
  • Encapsulation Technologies
    • Predictive Polymer Analytics™ (PPA™)
    • CSS® Encapsulation Equipment
    • Hydrogel & Cell Therapy Consultation
  • Therapeutic Challenges
    • Lack of Persistence
    • Poor Yield & Function after Freezing Cells
    • Immune Rejection of Encapsulant
    • Lack of Biocompatibility
    • Regulatory Hurdles
    • Different Therapies Need Unique Microenvironments
  • Success Stories
    • Antibodies (NovoSphere™)
    • Osteoarthritis Therapy (ViscoCell™)
    • Diabetes Treatment (EnduraCell™)
    • Cryopreservation (LiberaCell™)
    • Liver Disease (EnduraCell™)
    • CAR-T Cells (VitaCell™)
    • Cryopreservation (AegisCell™)
    • Extending the Life of Fresh Cells (LiberaCell™)
    • View All
  • Resources
    • Research & White Papers
    • News & Upcoming Events
    • Bio-Blog / Tech Notes
    • Videos & Webinars
  • Partner With Us
    • Contact Us
    • Investors
Follow Us:

Success Stories
Powered by Likarda

See how our encapsulation and delivery platforms are driving measurable impact and creating real-world results across a range of therapeutic applications.

  • Microscopy of Likarda's NovoSphere™ in action.
    Antibodies (NovoSphere™)
    Monthly mAb dosing achieved through lyophilized, extended-release formulation.

    Read Success Story
  • ViscoCell microscopy
    Osteoarthritis Therapy (ViscoCell™)
    Stem cell delivery improved joint retention and drove cartilage repair in osteoarthritis.
    Read Success Story
  • EnduraCells™ (the white circles) contained healthy insulin-producing human cells.
    Diabetes Treatment (EnduraCell™)
    Sustained blood glucose control without daily insulin injections in preclinical models.
    Read Success Story
  • Microscopy of cells preserved with LiberaCell™
    Cryopreservation (LiberaCell™)
    Fragile liver spheroids survive freezing with full function restored.
    Read Success Story
  • Microscopy of cells used with EnduraCell™
    Liver Disease (EnduraCell™)
    30-day functional liver spheroids outperforming alginate models.

    Read Success Story
  • VitaCell microscopy
    CAR-T Cells (VitaCell™)
    Encapsulation enabled controlled, localized release of CAR-T cells in glioblastoma, dramatically improving persistence and metabolic activity compared to unencapsulated controls.
    Read Success Story
  • Microscopy of Likarda's AegisCell hydrogel in action.
    Cryopreservation (AegisCell™)
    T-cells stayed viable and functional for 2 weeks on dry ice, matching LN2 storage.
    Read Success Story
  • Cells suspended under microscope
    Extending the Life of Fresh Cells (LiberaCell™)
    Fragile liver spheroids survive freezing with full function restored.
    Read Success Story
© 2025 Likarda
  • Privacy Policy
  • Terms
  • Site by Lundmark
Manage Cookie Consent

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember...and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Policy

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}